Pneumocystis carinii pneumonia PCP

AIDSTRIALS (AIDS Clinical Trials). The AIDSTRIALS database [80] provides information about AIDS-related studies of experimental treatments conducted under the FDA s investigational new drug (IND) regulations. AIDSTRIALS contains information about clinical trials of agents undergoing evaluation for use against AIDS, HIV infection, and AIDS-related opportunistic diseases such as Pneumocystis carinii pneumonia (PCP). Detailed information is supplied... 

The most common opportunistic diseases and their frequencies found before death in patients with AIDS between 1990 and 1994 were Pneumocystis carinii pneumonia (PCP), Mycobacterium avium complex, and cytomegalovirus disease. 

Alternative, also stereoselective, routes to allenic steroids take advantage of cationic cyclization reactions [108] or [2,3]-sigmatropic rearrangements [109]. For example, the allenic Michael acceptor 112 was prepared with 57% chemical yield by reaction of mestranol (111) with diethyl chlorophosphite and was found to inhibit the sterol biosynthesis of the pathogen responsible for Pneumocystis carinii pneumonia (PCP), the most abundant AIDS-related disease (Scheme 18.36) [110]. 

As an alternative therapy with concurrent leucovorin administration (leucovorin protection) for the treatment of moderate to severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), who are intolerant of or refractory to TMP-SMZ therapy, or for whom TMP-SMZ is contraindicated. 

Antimicrobial prophylaxis Cases of Pneumocystis carinii pneumonia (PCP) have been reported in patients not receiving antimicrobial prophylaxis. Therefore, administer antimicrobial prophylaxis for PCP for 1 year following transplantation. Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV disease. 

Pneumocystis carinii pneumonia (PCP) PO 750 mg twice a day with food for 21 days. Prevention of PCP PO 1500 mg once a day with food. 

Pneumocystis carinii pneumonia (PCP) prophylaxis PO 1 double-strength tablet... 

Dermatitis herpetiformis PO Initially, 50 mg/day. May increase up to 300 mg/day Pneumocystis carinii pneumonia (PCP) PO 100 mg/day in combination with trimethoprim for 21 days. 

A series of 2,7- and 3,6-bis-cationic carbazoles, for example, 49, shows activity against a rat model of Pneumocystis carinii pneumonia (PCP), and some are more potent and less toxic than the standard anti-PCP drug pentamidine <1997EJM781>. While no quantitative correlation was seen between anti-PCP activity, topoisomerase inhibition, and DNA binding, a minimal level of DNA binding was found to be necessary for antimicrobial activity. 

Computational Chemistry Studies of Antifolate Drugs for Treatment of Pneumocystis carinii Pneumonia (PCP) in AIDS Patients Trimetrexate and Analogues. ... 

HPI CJ is a 32-year-old man with acquired immunodeficiency syndrcMne (AIDS) (CD4+ cell count 160 cells/mm viral load 35,000 copies/mL) who presents to the clinic with altered taste sensation and difficulty swallowing. G is noted to have white plaques on the tongue and upper oral pharynx that are easily scraped off with a tongue depressor. PMH is significant for renal insufficiency secondary to his HIV. His antiretroviral regimen includes stavudine, lamivudine, and lopinavir/ritonavir and he is receiving TMP-SMX for Pneumocystis carinii pneumonia (PCP) prophylaxis. He has NKDA. 

The incidence of Pneumocystis carinii pneumonia (PCP) within the first year after transplantation is reported to be 3% to 5%. " Low-dose trimethoprim-sulfamethoxazole (TMP-SMX 400 mg/ 80 mg three times weekly) is effective in the prevention of PCP infections. Alternative agents include aerosolized pentamidine (300 mg every month), dapsone, and atovaquone. The duration of PCP prophylaxis is unclear. The risk of infection caused by P. carinii is likely to decrease as immunosuppression is reduced therefore, prophylaxis in patients requiring treatment for acute rejection may be appropriate. 

The acquired immune deficiency syndrome (AIDS) was first recognized by the medical community as a distinct clinical entity in 1981. This syndrome was described initially in a cohort of young homosexual men with profound immunologic deficits, Pneumocystis carinii pneumonia (PCP), and Kaposi s sarcoma. A retrovirus, human immunodeficiency virus type 1 (HIV-1) is the major cause of AIDS. A second retrovirus, HIV-2, also has been recognized to cause AIDS,... 

Pentamidine (4 mg/kg once a day for 14 days) is indicated in the treatment of Pneumocystis carinii pneumonia (PCP), prevention of PCP in high-risk, HIV-infected patients, and in the treatment of trypanosomiasis and visceral leishmaniasis. 

Balkovec, J.M., Black, R.M., Hammond, M.L., etal. (1992) Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J. Med. Chem. 35 194-198. 

The client with a CD4 count of less than 300/mm is at risk for developing Pneumocystis carinii pneumonia (PCP). Bactrim is prophylaxis for PCP. Normal levels for CD4 are 450-1400/mm. ... 

The folic acid analog trimetrexate is a competitive inhibitor of bacterial and protozoan dihydrofolate reductase. This compound is currently used as a treatment for Pneumocystis carinii pneumonia (PCP) in patients with immunocompromising conditions. 

Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer 2005 44(1) 55-62. 

---